Abstract: Statistical analysis of longitudinal outcomes is often complicated by the absence of observable values in patients who die prior to their scheduled measurement. In such cases, the longitudinal data are said to be "truncated by death" to emphasize that the longitudinal measurements are not simply missing, but are undefined after death. Recently, the truncation by death problem has been investigated using the framework of principal stratification to define the target estimand as the survivor average causal effect (SACE), which in the context of a two-group randomized clinical trial is the mean difference in the longitudinal outcome between the treatment and control groups for the principal stratum of always-survivors. The SACE is not identified without untestable assumptions. These assumptions have often been formulated in terms of a monotonicity constraint requiring that the treatment does not reduce survival in any patient, in conjunction with assumed values for mean differences in the longitudinal outcome between certain principal strata. In this paper, we introduce an alternative estimand, the balanced-SACE, which is defined as the average causal effect on the longitudinal outcome in a particular subset of the always-survivors that is balanced with respect to the potential survival times under the treatment and control. We propose a simple estimator of the balanced-SACE that compares the longitudinal outcomes between equivalent fractions of the longest surviving patients between the treatment and control groups and does not require a monotonicity assumption. We provide expressions for the large sample bias of the estimator, along with sensitivity analyses and strategies to minimize this bias. We consider statistical inference under a bootstrap resampling procedure.
Introduction
In randomized clinical trials (RCTs), researchers often wish to determine the causal effects of the treatment assignment on longitudinal outcomes ascertained at one or more designated follow-up visits. Examples include biomarkers for nutritional status, inflammation, cardiovascular function, as well as assessments of quality of life. However, statistical analysis of longitudinal outcomes is often complicated by the absence of observable values in patients who die prior to their scheduled measurement. This problem has been referred to as truncation-by-death [1] [2] [3] to emphasize that the longitudinal measurements are not missing in the usual sense, but are undefined after death.
In the presence of truncation by death, a naïve comparison of the longitudinal outcome between survivors in the randomized groups is subject to bias, since the analysis conditions on survival, a post-randomization outcome. For example, if survival is positively associated with favorable values for the longitudinal outcome, the naïve analysis may be biased against a treatment that favorably affects survival, since more higher-risk patients will die prior to measurement of the longitudinal outcome in the control group. If the research objective is to provide a comprehensive assessment of patient outcome, it is natural to circumvent this problem by defining a composite endpoint incorporating both the longitudinal outcome and death. Examples include the use of time-to-event endpoints defined by time until death or a designated unfavorable change in the longitudinal outcome, and the designation of ordinal composites in which death is assigned the lowest score [4, 5] . Because the composite outcomes are defined in all patients, selection on survivors is avoided, and the sanctity of the randomized design is preserved. However, often the objective is to determine the effect of the treatment specifically on a longitudinal endpoint. In this explanatory context, incorporating survival as a component of a composite endpoint constitutes a diversion from true scientific objective. Since treatment effects on mortality and the longitudinal outcome may operate through different mechanisms, incorporating mortality in a composite could obscure the treatment effect specifically on the longitudinal outcome.
When the proportion of deaths is low, this conundrum is often addressed by applying longitudinal methods that treat death as a type of censoring event, thus implicitly or explicitly imputing values for the longitudinal outcome after death [6] . These methods include application of likelihood-based inference to the longitudinal outcome, ignoring deaths, thus implicitly assuming non-informative censoring by death. Alternatively, likelihood-based inference may be performed using joint models incorporating both death and the longitudinal outcome, or by using inverse probability of censoring weighting methods. However, all of these methods have the conceptual disadvantage of applying inferences for mean changes in the longitudinal outcome to hypothetical virtual populations without death. There is some controversy as to whether methods for censored data are ever applicable when some data are unobserved due to death. Some researchers have argued that it is never appropriate to treat planned measurements after death as censored [2, 7] . Others [8] have stipulated that if the factors leading to most of the deaths are distinct from the factors that determine the longitudinal outcome, then it can be reasonable to postulate values that the longitudinal outcome would have taken in a hypothetical population in which the patients had not died. In this paper, we do not take a position as to whether such virtual outcomes are ever plausible, but focus on the setting where the proportion lost due to death is relatively high and causes of death may be associated with the longitudinal outcome, in which case there is general agreement that it is necessary to treat intended measurements after death as undefined.
Recently, progress with the truncation by death problem has been made using the framework of principal stratification, as formalized in a unifying paper of Fangakis and Rubin [9] . The target of inference under the principal stratification framework has been framed as the survivor average causal effect (SACE), defined as the mean difference in the longitudinal outcome between the treatment and control interventions for the principal stratum of always-survivors -i.e. those patients who would survive to the scheduled measurement time irrespective of whether the patient is assigned to the treatment or control group. The principal stratification framework has the advantage of avoiding stipulation of virtual outcomes after death and has been proven to be useful both in clarifying problems with standard methods and in establishing bounds and sensitivity analyses which characterize the range of values for the SACE which are consistent with the data.
However, estimation of the SACE is complicated in practice of due to the fact that the principal stratum of always-survivors is unobservable. As a result, strong identifiability assumptions are usually required to obtain practical results. In particular, much work has invoked the assumption of monotonicity, which stipulates that the patient would survive to the designated follow-up time under the treatment whenever the patient would do so under the control [10, 11] . This assumption will typically be untenable in two-sided testing situations where the possibility of an adverse treatment effect in some fraction of patients cannot be ruled out. A further difficulty is that even if the monotonicity assumption is plausible, bounds and sensitivity analyses require consideration of further non-identified associational parameters, imposing substantial demands on the investigator's judgment.
In this paper, we propose to mitigate these difficulties by introducing a new estimand, the balanced-SACE, defined as the average causal effect on the longitudinal outcome in a subset of the always-survivors, which is balanced in a certain sense with respect to the potential survival times under the treatment and control interventions. The intuition for our approach derives from work by Robins [12] , who applied rankpreserving models for potential survival times to address truncation by death problems in a competing risk setting. The rank-preservation assumption allows the potential survival time of a patient on the intervention to which the patient was not assigned to be determined from the survival time observed on the patient's assigned intervention, thus identifying the principal stratum of always-survivors. Because the rank-preserving assumption is likely to be violated in practice, our development includes a characterization of the bias that results when it is violated, along with sensitivity analyses and strategies to minimize this bias. The sensitivity analyses depend on non-identified parameters, but satisfy symmetry conditions that we hope will facilitate implementation and interpretation.
This manuscript is organized as follows. Section 2 introduces our notation and contrasts the two approaches to identify the principal stratum of always-survivors based on monotonicity and rank-preserving assumptions. In Section 3, we define the balanced SACE and describe our proposed estimator. This estimator is asymptotically unbiased if either the rank-preserving assumption holds or a symmetry condition involving a contrast between conditional expectations of the longitudinal outcome is satisfied. This section also describes a strategy for sensitivity analysis. In Section 4, we propose methods for reducing bias resulting from violation of the rank-preserving assumption. Section 5 presents a small simulation study examining the large-sample bias of the proposed estimators, and Section 6 considers statistical inference using the bootstrap. We illustrate the proposed approach with an example drawn from a randomized trial of dialysis patients in Section 7, and close with a discussion.
Monotonicity and rank-preserving assumptions
We consider a two-group randomized trial with longitudinal outcome Y. For simplicity, we assume Y is measured at a single follow-up time J. For the ith patient, let A i = 0 designate assignment to the control group and A i = 1 assignment to the treatment group, and let T i denote the time of death. Also, let Y i denote the observed Y if T i ≥ J, with Y i undefined if T i < J. Let C i denote a common right censoring time for ascertaining both T i and Y i which is assumed independent of T i and Y i . Thus, we observe A i , W i = min(T i , C i ), an indicator δ i = 1 if T i ≤ C i and δ i = 0 otherwise, and Y i if J ≤ W i . We further define the potential survival times T i (0) and T i
(1) as the survival times that would have been observed were the patient assigned to the control or treatment groups, respectively. We assume for simplicity of exposition that the T i (g) are continuous random variables with strictly increasing distribution functions. Also define Y i
, J ≤ T i
, to be the value of Y i that would have been observed if patient i were assigned to the control group, and Y i (1) , J ≤ T i (1) , to be the value of Y i that would have been observed if patient i were assigned to the treatment group.
We invoke the standard consistency and stability assumptions of causal inference, under which
, where g 2 f0; 1g. We are concerned with the situation in which the research hypothesis is expressed specifically in terms of the longitudinal outcome, and not mortality, but we must account for occurrences of T i < J. The pair (T i (0) , T i (1) ) partitions the randomized cohort into four groups: LL = subjects who would survive to time J irrespective of the treatment (the always survivors); DL = subjects who would survive with the treatment but not the control; LD = subjects who would survive with the control but not the treatment; DD = subjects who would die irrespective of the treatment. The causal effect Y i Most previous attempts to estimate the SACE have invoked the assumption of monotonicity, which stipulates a uniform treatment effect such that LD= f (e.g., T
(1) =1 whenever T (0) =1). The monotonicity assumption is sufficient to identify the probabilities of each of the remaining principal strata LL, DL, and DD. Given monotonicity, the SACE can be identified by specifying one additional parameter related to the difference in the mean of Y (1) between LL and DL. In particular, under monoticity, the SACE is given either (Chiba and VanderWeele, 2011) . Here, E(Y|A=1,T≥J) -E(Y|A=0,T≥J) is the difference in the observed means of Y among survivors in the treatment and control groups, and ξ 1 or ξ 2 are non-identified parameters which must be supplied by the investigator. Typically, a sensitivity analysis is performed based on plausible ranges for ξ 1 or ξ 2. Alternatively, the investigator may proceed without invoking the monotonicity assumption; in this case, three non-identified parameters must be specified: one parameter to determine Pr(LD), a second to determine E(Y
|LD), and a third to determine E(Y
|DL) [13, 14] . A major challenge with these approaches is that the non-identified parameters E(Y
|DL) are associational rather than causal; hence, the investigator must make judgments concerning the combined strength of the effects of factors that jointly influence the longitudinal outcome and mortality, and typically, many of these factors are unknown to the investigator.
Next, we consider the determination of the SACE under a rank-preserving model in which the potential survival times are related by T (1) = h(T (0) ) for some 1 -1 function h(). Under the rank-preserving model, h() is determined by the survival functions F 0 (t) and F 1 (t) of the survival times in the control and treatment groups as h(t) = F 1 -1 (F 0 (t)). The principal stratum LL consists of control group patients with T i ≥ h -*(J), and treatment group patients with T i ≥ h*(J), where h*(J) = max{J, h(J)} and h -*(J) = max{J, h -1 (J )}.
Hence, the SACE is identified directly as the difference in the mean of Y between treatment patients with T i ≥ h*(J) and control patients with T i ≥ h -*(J). The relationship between the rank-preserving and monotonicity assumptions is depicted in Figure 1 for a hypothetical example in which the treatment extends survival by approximately 1/3, and the longitudinal outcome is measured at time J = 3 years. Monotonicity is satisfied because h(t) does not intersect LD. Under rank preservation, all subjects fall on the thick line (T (0) , h(T (0) )); monotonicity only excludes subjects from the LD quadrant. Thus, rank preservation is a stronger assumption which implies monotonicity. Under the approach described using the monotonicity assumption, the mean of Y for the control group is first averaged over LL and subtracted from the mean of Y for the treatment group over DL S LL. This difference is not a causal comparison since DL is included in the mean Y for the treatment group but not for the control group; hence the need to correct for the resulting bias by adding a non-identified parameter based on the difference in the mean of Y (1) between LL and DL. This latter step can be avoided under the rank-preserving model, since one can directly compare the mean of Y over the intersection of (T (0) , h(T
)) with LL in both the treatment and control groups.
In contrast to the monotonicity assumption, the rank-preserving assumption treats the treatment and control groups symmetrically, consistent with the two-sided hypothesis testing. Unfortunately, as illustrated in Figure 1 , the rank-preserving assumption is usually biologically implausible, as it implies a deterministic relationship between T
(1) and T (0) . Hence, the rank-preserving assumption must be relaxed for practical applications.
Relaxing the rank-preserving assumption
To relax the rank-preserving assumption, we introduce the balanced SACE, which represents the average causal effect of the treatment on a particular subgroup of the LL stratum. Define J as above, and let
The relationship between the balanced SACE and the SACE is illustrated in Figure 2 , which presents a scatter plot of the joint distribution of T (1) and T (0) for a simulated dataset where J = 3 years. The function h given by the survival functions of Figure 2 ; the deviations of the points in the scatter plot from h represent violations of the rank-preserving assumption. However, h retains the interpretation of characterizing equivalent survival quantiles for T (0) and T
; for example, equal proportions of patients survived at least 3 years under the control and 4.15 years under the treatment. The principal stratum LL contains all patients for whom T (0) ≥ 3 years and T (1) ≥ 3 years. P 01 includes those subjects for whom T i (0) ≥ 3 years and T i (1) ≥ 4.15 years; as illustrated by this example, it is readily seen that P 01 is always a subset of LL.
In the example, the component of LL which is not included in P 01 consists of patients who would survive 3 years under the control and would have survived between 3 and 4.15 years under the treatment. Because these patients failed to survive 4.15 = h(3) years under the treatment, they represent a subgroup whose treatment effect was smaller than the expected treatment effect indicated by h in the sense that each patient in LL\P 01 has a smaller survival percentile under the treatment than under the control. Our rationale for restricting the balanced SACE to P 01 rather than LL is that we wish our inferences for the treatment effect on Y to be as independent as possible from treatment effects on survival. We exclude LL\P 01 because these patients experienced smaller than the expected treatment effects on survival. If there is a relationship (positive or negative) between survival and the longitudinal outcomes, inclusion of these patients could skew our assessment of the causal effect on Y. By contrast, P 01 represents a subset of LL which is "balanced" with respect to treatment effects on survival.
The following symmetry lemma characterizes the relationship of the identifiable quantity E(
with the balanced SACE when the rank-preserving criterion is violated:
Symmetry Lemma: and h ÀÃ ðJÞ, respectively. It follows from the symmetry lemma that with randomized treatment assignment, Δ
where R 0 and R 1 represent the subsets of the control and treatment group patients with nonmissing responses Y i . Hence, (1 -Ψ) × (δ -Δ) represents the large-sample bias of ê(BSACE). The first term, 1 -Ψ, is equal to 0 under the rank-preserving assumption. The quantity δ is the difference between the mean of Y under treatment for the subgroup P 1\0 and the mean of Y under the control on P 0\1 . The second term, δ -Δ, is 0 if this difference equals the average causal effect of interest. Because the asymptotic bias (1 -Ψ) × (δ -Δ) is a product, ê(BSACE) consistently estimates the balanced SACE if either the rank-preserving assumption is satisfied or if the difference between the mean values of Y under the treatment on P 1\0 and under the control on P 0\1 is equal to the average causal effect Δ. Further, because Pr(P 0\1 ) + Pr(P 1\0 ) + Pr(P 01 ) = Pr(P 0\1 ) + Pr(P 0\1 ) + Pr(P 01 ) = Pr(P 0\1 ) + Pr(P 0 ) ≤ 1, it follows that 1 -Ψ is bounded above by (1-Pr(P 0 ))/Pr(P 0 ) (final column of Table 1 ). If we assume the existence of monotonic transformations of T (0) and T (1) that form a bivariate normal distribution, then stricter upper bounds can be constructed in terms of Pr(P 0 ) and the correlation ρ between the normally distributed transformed potential death times (left four columns of Table 1 ). ρ = 1 corresponds to the rank-preserving assumption with 0 bias. More generally, it may be expected that the majority of patients with longer survival times under the control would also have longer survival times under the treatment even if rank preservation is not satisfied. Hence, it will often be plausible to assume ρ≥ 0, and often that ρ is somewhat greater than 0, perhaps ≥0.5. For example, if Pr(P 0 ) = 0.80, the upper bound for 1 -Ψ is 0.20 if ρ ≥ 0 and 0.14 if ρ ≥ 0.50. Even with substantial deviations of δ from Δ, the maximum bias is likely to be small enough for many applications when Pr(P 0 ) ≥ 0.80, say. On the other hand, for smaller Pr(P 0 ), inferences on Y must rely heavily on the assumption that δ is close to Δ or that ρ is close to 1. Sensitivity analyses can be performed by correcting Δ with a set of plausible values for Ψ and (δ -Δ) to obtain a set of corrected estimates ΔÀ ð1 À Ψ Þ Â ðδ À ΔÞ. If the investigator is willing to entertain virtual potential outcomes Y
(1) on P 0\1 and Y (0) on P 1\0 , then understanding might be aided by noting that
The first bracketed expression can be interpreted as the component of the bias δ -Δ resulting from effect modification (i.e. the difference in the average treatment effect on Y between those who would survive under one treatment but not the other and those would survive under both treatments), while the second bracketed term can be viewed as the component resulting from confounding (i.e. the difference in the average of the potential outcomes Y (1) and Y (0) between P 1\0 and P 0\1 ). The required assessments of effect modification and confounding are somewhat similar to those required by sensitivity analyses addressing confounding in observational studies.
In some cases, researchers may tolerate the use of virtual Y to help conceptualize the sensitivity analyses, with some security that virtual Y are avoided in the balanced SACE itself. If conceptualization of the virtual Y (1) on P 0\1 and Y (0) on P 1\0 is not tenable, then investigators may postulate plausible ranges of
|P 0\1 ) -Δ without resorting to eq. [1] . For this purpose, it can be helpful to note that
where the bracketed terms represents confounding/selection bias terms analogous to the sensitivity parameters Δ 1 or Δ 2 required to estimate the SACE under monotonicity. Judgments regarding eq.
[2] may sometimes be more straightforward than those required for Δ 1 or Δ 2 due to the symmetric role of the treatment and control groups, which may lead to cancelation of biases. We close this section by noting the balanced SACE consistently estimates E Y ð1Þ jP
irrespective of whether the rank-preserving assumption is satisfied. In the absence of rank preservation, this quantity does not represent an average causal effect, but nonetheless may remain a plausible estimand in certain contexts. We return to this issue in Section 8. 
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Steps to reduce bias
We consider two strategies to reduce the bias in estimates of the balanced SACE, which may be applied individually or in combination.
Conditioning on subgroups with high survival probability
Because the upper bound for 1 -Ψ is a decreasing function of Pr(P 0 ) = Pr(P 1 ), it is logical to restrict the analysis to a subgroup of patients for whom the probability of survival to time J is relatively high (≥ 0.8, say). To carry out this approach, for a given subgroup S, let F Sg (t) = Pr[T (g) > t| S] denote the survival function for T (g) on S for g = 0,1, and define h S * (J) = max(J, h S (J)) and h S -* (J) = max(J, h S -1 (J)), where h S (J) = F S1 -1 (F S0 (J)). Natural restrictions of P 0 and P 1 on S are P S0 ¼ fi ε SjT
Consider the objective of determining a maximal subgroup S which can be defined in terms of a designated set of baseline covariates Z such that 0.5 × {F S0 (J) + F S1 (J)} ≥ τ for some threshold τ. Under equal allocation of patients to the treatment and control groups, 0.5 × {F S0 (t) + F S1 (t)} is the survival function for the observed failure time T given S, which we denote F S (t). If we further assume that log(T) is related to Z by an accelerated failure time model with survival function H((log(t) -Z β)/ σ), the maximal S which can be defined from Z such that F S (J) ≥ τ is given by the smallest φ such that S ¼ fijZ i β ! φg satisfies E i ԑ S fHððlogðJÞ À Z i βÞ=σÞg ≥ τ. We denote the balanced SACE on the maximal S as the (Z, τ-restricted)-balanced SACE. In practice, given a consistent estimateβ of β (e.g. the MLE under the assumed accelerated failure model), the (Z, τ-restricted)-balanced SACE can be consistently estimated by defining ê(BSACE) on the subgroup S(Z, τ), where S(Z, τ) is estimated based on the smallest φ such that 1 CardðSðZ; τÞÞ
and Card S(Z, τ) denotes the number of subjects such that Z iβ ! f. Because the interpretation of the (Z, τ-restricted)-balanced SACE is contingent on the patient population S(Z, τ), it will be useful to accompany estimates of the (Z, τ-restricted)-balanced SACE with summaries of the baseline covariate distributions on S(Z, τ).
Stratification
As illustrated in Figure 2 , P 1\0 consists entirely of patients whose survival time percentile on the treatment exceeds their survival time percentile under the control, while P 0\1 consists of patients whose survival time percentile on the control exceeds the percentile of their survival on the treatment. It follows that a baseline factor which modifies the treatment effect on survival may be imbalanced between P 1\0 and P 0\1 . If the baseline factor is also related to the potential outcomes Y (0) and Y (1) , its imbalance between P 1\0 and P 0\1 could lead to bias in ê(BSACE) as an estimator of the balanced SACE. In this setting, it is natural to consider a stratified approach. Let Z denote a vector of baseline covariates that includes factors considered to be possible effect modifiers for T and possible predictors of Y. Let h Z denote the quantile-quantile regression function defined conditionally on Z by and define P 0 (z) and P 1 (z) analogously. Then we may define the (Z-adjusted)-balanced SACE as We assume the requisite modeling assumptions so that F Z0 and F Z1 can be consistently estimated under an appropriate survival model; e.g. by fitting proportional hazards or accelerated time models relating T (1) and T (0) to Z. Alternatively, if Z can be summarized by a limited number of discrete strata, we can substitute consistent estimates of the strata-specific survival functions to consistently estimate h z . Given a consistent estimatorĥ z for h z , we can estimate the (Z-adjusted)-balanced SACE bŷ where The first term within the integral of eq. [3] , (1-Ψ (z)), is equal to 0 for all z if the rank preservation assumption holds locally, conditional on Z, and the second term, ðδðzÞ À ΔðzÞÞ, is identically 0 if the difference between the mean of Y (1) on P 1\0 (z) and Y (0) on P 0\1 (z) is equal to the average causal effect of the treatment on Y over P 01 (z) within strata defined by Z.
If it is plausible to consider virtual potential outcomes Y (1) on P 0\1 and Y (0) on P 1\0 for the purpose of selecting the stratification factors, then for each z,
The second bracketed term of the right hand side of eq. [4] is equal to 0 if Q 0|1 is conditionally independent of (Y (1) + Y
)/2 given Z=z and (P 1\0 (z) S P 0\1 (z)), where Q 0|1 indicates membership in P 1\0 (z) given membership in P 1\0 (z) S P 0\1 (z). Thus, if the first bracketed term in eq. [4] is assumed to be 0, then we may say heuristically that ê z (BSACE) consistently estimates the (Z-adjusted)-balanced SACE if the process by which "nature selects" patients who belong to P 1\0 (Z) rather than P 0\1 (Z) is conditionally independent of (Y (1) +Y (0) )/2 given Z. This reasoning suggests that Z should include factors which modify the effect of the treatment on mortality which are also associated with Y. Analogous to adjustment for covariates when estimating causal effects from observational data, an important caveat to the stratification approach is that there is no guarantee that stratifying by a particular baseline factor will reduce the asymptotic bias in the absence of untestable assumptions. Finally, we note that the two bias-reduction approaches of this section can be applied jointly, by first restricting the analysis to a subgroup S(Z 1 , τ) based on a set of prognostic baseline covariates Z 1 , and then estimating the (Z 2 -adjusted)-balanced SACE on S(Z 1 , τ) based on a set of potential effect modifiers Z 2 .
Simulation to assess large-sample bias
We performed a small simulation for the large-sample setting in which we wish to estimate the treatment effect on Y at 3 years. In the large-sample setting, we are essentially comparing E(
| P 0 ) to the balanced SACE. We assumed that data are available for 1,000 patients randomized with equal allocation to the treatment and control groups, and that survival is ascertained for all patients until year 7. Let Z p and Z m respectively denote normally distributed and dichotomous baseline covariates which are standardized to have mean 0 and variance 1 and let: and that ε ð0Þ and ε ð1Þ are independent of Z p and Z m . We assume that log(T
) and log(T (1) ) each have standard deviation 0.54 (so the ratio of the 10th and 50th percentiles of the distribution of T (g) is 0.5 for normally distributed ε ðgÞ ; g ¼ 0; 1), that the median of T (0) is 4 years, and that α int,1 = α int,0 + log(1.6),
representing a 60% extension of survival by the treatment. For each scenario, we also took α p,0 = α p,1, so Z p represents a prognostic factor for survival, and α m,1 = -1 × α m,0 , so Z m represents an effect modifier of the treatment on survival. We set γ m;1 ¼ γ m;0 ¼ 2 in each scenario. Finally, we scaled the coefficients α p,g and α m,g so that Z p α p,g + Z m α m,g accounted for 70% of the variance of log(T (g) ), g = 0,1. ), (γ p;g ; γ m;g γ 0;g ; γ 1;g ), and the shape of the joint distribution of ðε ð0Þ ; ε ð1Þ Þ. We performed 1,000 independent simulations for each scenario. For each scenario, the table provides 1) the bias relative to the balanced SACE of the naïve method estimate defined by the mean of Y among survivors to year 3 in the treatment and control groups, 2) the bias relative to the balanced SACE of ê(BSACE) as defined in Section 3, 3) the bias relative to the (Z p τ-restricted)-balanced SACE of the subgroup estimator defined in Section 4 restricted to patients with Z p > 0, and 4) the bias relative to the (Z p τ-restricted, Z m -adjusted)-balanced SACE of the stratified subgroup estimator of Section 4 which is both restricted to patients Z p > 0 and stratified by Z m . Scenarios 1 and 4 with α m,0 = α m,1 = 0 and ρ eps = 1 satisfy the rank-preserving condition with and without stratification on Z m and with and without conditioning on Z p > 0; hence, each variant of the balanced SACE produced approximately unbiased estimates of their associated estimands. Although they violate the rankpreserving assumption due to ρ eps < 1, scenarios 2 and 3 satisfy δ = Δ, so that again each variant of the balanced SACE produced approximately unbiased estimates. In scenarios 5 and 6, δ -
. Hence, the unconditional ê(BSACE) has a moderate negative bias whose magnitude is greater when the correlation between ε (0) and ε (1) is low (scenario 6) than when it is high (scenario 5). This bias in the balanced SACE is reduced when the analysis is conditioned on Z p > 0. In scenarios 7-9, the effect modification by Z m (due to α m,0 = 1 ≠ α m,1 = -1) implies that δ -Δ ≠ 0 for the unconditional ê(BSACE) , but that δ -Δ = 0 when the analysis is stratified by Z m . Hence, the unconditional ê(BSACE) exhibits a negative bias which is essentially eliminated after stratification on Z m . Scenarios 10-12 also exhibit effect modification by Z m , but we still have δ -Δ ≠ 0 after stratifying by Z m . In this situation, the bias in ê(BSACE) is reduced but not eliminated after stratification by Z m ; however, the bias is largely eliminated after both stratification on Z m and conditioning on Z p > 0. Scenarios 13 and 14 do not exhibit effect modification by Z m and satisfy γ p,0 = γ p,1, but still have δ -Δ ≠ 0 because (γ 0,1, γ 1,1 ) ≠ (γ 0,0, γ 1,0 ). In these scenarios, the unconditional ê(BSACE) estimator exhibits a small bias that persists after stratification by Z m but is attenuated after conditioning on Z p > 0. Scenarios 15 and 16 exhibit effect modification by Z m and (γ 0,1, γ 1,1 ) ≠ (γ 0,0, γ 1,0 ); here, there is a moderate bias in the unconditional ê(BSACE) which is partly attenuated by stratification by Z m and attenuated further by both stratification by Z m and conditioning on Z p > 0. Finally, scenarios 17 and 18 exhibit δ -Δ ≠ 0 because the joint distribution of ðε ð0Þ ; ε ð1Þ Þ is asymmetric; however, in these cases, the resulting bias is negligible. In each scenario, the naïve estimator exhibits a substantial negative bias (against the treatment) due to the assumed positive effect of the treatment on survival.
6 Use of the bootstrap for inference The ACC has been shown to have an asymptotic normal distribution under general regularity conditions [16] . balanced SACE under the symmetry conditions described Section 3, can then be obtained using the corresponding quantiles of the bootstrap distribution. Table 3 presents the results of a small simulation study of the performance of the proposed bootstrap confidence intervals. We took the survival time T and right censoring time C to be independent exponential random variables with rates λ Tg and λ Cg for A = g, g = 1,2, and simulated Y at time J = 3 as A 1g × log(T) + A 2g × (T) + ε, where VarðεÞ ¼ σ 2 . For the base case scenario, we took λ T1 = λ T2 = 1/6 (so that Pr(T ≥ 3) = 0.61 for g=1,2), λ C1 = λ C2 = 1/12 (so that Pr(C ≥ 3) = 0.78, A 11 = A 12 = 1 and A 21 = A 22 = 0 (indicating no treatment effect on Y when λ T1 = λ T2 ), σ 2 = 1, and N group = 1,000, corresponding to the large-sample setting.
Since our focus here is on the sampling distributoin of ê(BSACE), we have expressed the bias and coverage probabilities of ê(BSACE) relative to the estimable quantity E(
|P 0 ). The first 7 scenarios evaluate the large-sample performance of the bootstrap. The average bias across the bootstrap samples is close to 0 and the 95% coverage probabilities close to 0.95 across Scenarios 1-6 in which the conditional distribution of Y given T was identical in the two treatment groups. A small bias in ê(BSACE) is observable in Scenarios 7 and 9. This appears to be due to fact thatĥ Ã KM ðJÞ ¼ max½ĥ KM ðJÞ; J is constrained to be ≥J, which leads to a small-sample bias inĥ Ã KM ðJÞ when h Ã ðJÞ is equal or close to J. The bias inĥ Ã KM ðJÞ may lead to bias in the estimated balanced SACE when the conditional distribution of Y given T differs between the treatment and control groups in a way that depends on T, which is the case in these scenarios.
Example
We illustrate concepts using the Hemodialysis (HEMO) study, a 2 × 2 factorial randomized trial of the effects of dialysis dose and membrane flux on mortality and morbidity performed between 1995 and 2001 in 1,846 hemodialysis patients assigned to 15 clinical centers in the United States. Patients were followed 1-7 years depending on their enrollment date. Reflecting the high mortality of hemodialysis patients, 871 (47.1%) of the randomized patients died before the end of follow-up. The trial's primary analysis found no significant benefit on mortality of either the dose (hazard ratio (HR) = 0.96, 95% confidence interval (CI): 0.84-1.10, p = 0.53) or flux (HR = 0.92, 95% CI: 0.81-1.05, p = 0.23) intervention. A systemic investigation of possible baseline effect modifiers indicated a possible interaction between the dose treatment and gender, and in women, the HR was 0.81, 95% CI: 0.67-0.97, p = 0.02 [17, 18] .
We consider the effect of the dose intervention on the change from baseline to 3 years follow-up in the serum albumin concentration. Serum albumin is a biomarker used to represent nutritional status and inflammation and is strongly associated with mortality in dialysis patients.
Three-year serum albumin values were obtained in 690 (37%) of 1,846 randomized patients. A total of 602 (33%) died prior to 3 years, 327 (18%) were administratively censored due to the end of the study, and the remaining 227 (12%) were otherwise lost to follow-up or had missing albumin data at 3 years. The Kaplan-Meier estimates of the probabilities of 3-year survival were 0.60 and 0.63 in the standard and high dose groups, with point estimatesĥ ÀÃ KM ðJÞ andĥ Ã KM ðJÞ of 3.00 and 3.27 years, respectively. Among men, estimated 3-year survival probabilities were 0.63 and 0.59 in the standard and high dose groups, witĥ h ÀÃ KM; men ðJÞ = 3.31 andĥ Ã KM; men ðJÞ = 3.00 years. Among women, reflecting the trend for a benefit of the high dose intervention on survival, the corresponding estimated survival probabilities were 0.58 and 0.66, withĥ ÀÃ KM; women ðJÞ = 3.00 andĥ ÀÃ KM; women ðJÞ = 3.63 years. The percent of females in P 0 and P 1 were 52.6% and Table 3 Bootstrap simulation results*.
Scenario description
Deviation from base case 57.4%, respectively. Thus, the direct comparison of the change in serum albumin between P 0 and P 1 by the unstratified balanced SACE may be moderately confounded by sex. Table 4 summarizes quantities relevant to the estimation of the unstratified balanced SACE and the sexstratified balanced SACE on change in serum albumin, first without restriction for the full study population and then restricted to patients whose predicted median survival from baseline factors exceeded 1,000 days or 2,000 days under a Weibul model. The predictor variables in the Weibull model were age, sex, race, years of dialysis, and baseline levels of serum albumin, body mass index, serum creatinine, Karnofsky score, SF-36 Physical Composite Score, and the Index of Coexisting Disease [19] . Among the full study population, the estimated proportion of patients in P 0 ¼ fij T As illustrated by the middle rows of the table, the baseline levels of prognostic covariates are substantially more favorable in the restricted populations; this must be taken into account in interpretations of the corresponding restricted balanced SACEs. The unstratified and sex-stratified balanced SACE estimates (bottom two rows) of the dose effect are slightly more favorable to the high dose intervention than are the naïve estimates, reflecting a slight trend for greater 3-year survival in the high dose group, although none of the estimates approached statistical significance at the 0.05 level. Although sex was somewhat imbalanced between the estimated P 0 and P 1 , this apparently did not substantially impact the balanced SACE estimates, as the unstratified and sex-stratified estimates of the balanced SACE are similar. As described in Sections 3 and 4, the balanced SACE estimates given in the bottom two rows of Table 4 may be biased in the absence of the rank-preserving (or local rank preserving) assumption if δ -Δ ≠ 0. To illustrate a possible sensitivity analysis strategy, suppose that it is considered unlikely that the magnitude of the bias term δ -Δ exceeds 0.30 of 1 standard deviation of the change in serum albumin (0.30 × 0.37 g/dL = 0.112 g/dL), and that it is considered likely that ρ ≥ 0.5. These ranges of δ -Δ and ρ give adjusted point estimates for the sex-adjusted balanced SACE ranging from 0.029 -0.27 × (0.112) = -0.001 to 0.029 + 0.26 × (0.112) = 0.059 g/dL without restriction, and from -0.017 -0.14 × (0.112) = -0.033 to -0.017 + 0.14 × (0.112) = -0.001 for the cohort with predicted survival >2,000 days. The uncertainty in the asymptotic bias is substantially reduced for the restricted balanced SACE; however, this comes at the statistical cost of reduced T. Greene et al.: The Balanced Survivor Average Causal Effect precision and the possible interpretational cost of changing the study population. To the best of our knowledge, this is the first analysis to employ the mapping from the distributions of T (0) to T (1) to define the parameter of interest; this idea was mentioned previously by Robins [8, 20] .
Discussion
Principal stratification provides a natural framework for settings in which the research objective requires estimation of average causal effects in "emergent" subgroups which cannot be fully determined at baseline [21] , as occurs when the goal is to estimate the treatment effect on a longitudinal outcome among survivors. Similar issues apply when patients undergo a clinical event, such as end-stage renal disease, which either precludes further follow-up measurements or renders such measurements uninterpretable. In contrast to most research applying principal stratification, we have avoided monotonicity requirements for survival, and instead have investigated average causal effects among survivors under symmetry conditions that extend a rank-preserving model for the potential survival times. This symmetric formulation is invariant to the labeling of the treatment and control groups and may be more appealing than methods requiring monotonicity in RCTs with two-sided hypotheses, or in studies in which the investigators cannot rule out adverse treatment effects on survival in some patients. Given a longitudinal outcome Y measured at time J, previous work using principal stratification has focused on estimation of the average causal effect on Y in the principal stratum LL of patients who would survive until time J on both treatments (referred to as the SACE). We propose a modified version of the SACE, which we have called the balanced-SACE, in which the causal effect on Y is averaged over a subset of LL, denoted P 01 , which includes equal proportions of patients who survive beyond the same percentile in the survival distribution in the two treatment groups. Our formulation views the research objective as estimating the treatment effect on Y while minimizing the role of death. From this perspective, for a treatment improving survival, inclusion of LL\P 01 in the estimand is likely to introduce a dependence of inferences concerning the treatment effect on Y on the treatment effect on T, since this subset consists of patients whose individual potential survival time percentile is lower with the treatment than it is with the control. Since individual-level treatment effects on survival may often correlate positively with favorable individual-level treatment effects on Y, exclusion of LL\P 01 may be necessary to avoid penalizing a treatment which improves survival.
An advantage of using the balanced-SACE as the estimand is that the asymptotic bias of a straightforward comparison of mean of Y for the treatment group on P 1 and for the control group on P 0 can be expressed by a simple expression, (1 -Ψ ) × (δ -Δ), which can be used for sensitivity analyses. Here, 1 -Ψ = 1 -Pr(P 01 )/Pr(P 0 ) defines the extent to which violation of the rank-preserving condition leads divergence between the subgroup P 1 would survive to h * (J) with the treatment and the subgroup P 0 who would survive to h -* (J) with the control. This term is bounded above by (1-Pr(P 0 ))/Pr(P 0 ), which declines toward 0 as the proportion Pr(P 0 ) of control patients who survive to h -* (J) increases toward 1. The second term (δ -Δ) characterizes the deviation of EðY ð1Þ jP 1n0 Þ À EðY ð0Þ jP 0n1 Þ from the average causal effect on P 01 .
Section 4 details two strategies, stratification on effect modifiers for survival, and restriction of the analysis to a subgroup with baseline covariates associated with increased survival, that may be used to limit the asymptotic bias in the estimated balanced SACE. A potential criticism of these strategies is that the estimand changes depending on the stratification or prognostic factors. In particular, (Z, τ-restricted) estimates replace the unrestricted balanced SACE, defined as the average causal effect on Y on P 01 , with the average causal effect on a subset of P 01 with higher conditional survival probability based on observed baseline covariates Z. At first glance, this strategy may appear to dodge the issue, since we have replaced a difficult problem, estimation of the balanced SACE on all of P 01 , with the simpler problem of estimating the balanced SACE on a subset with a higher of survival based on observable baseline factors. However, our perspective is that if P 01 contains a high percentage of patients whose survival probabilities given available baseline data are low, then estimation of the baseline-SACE on P 01 incurs a high risk of bias and the practical interpretation of the average causal effect on P 01 loses clarity. This concern reflects a common criticism of principal stratification approaches that it is difficult to take action based on estimands which are defined on subsets that cannot be identified at baseline [21] [22] [23] . Implementation of Z, τ-restriction, as proposed here, can be viewed as mitigating this drawback by assuring that the average causal effect applies to a large majority of patients within a definable subgroup. This is analogous in some respects to the common practice in the application of propensity score methods of restricting the target of inference to strata in which there are sufficient treated and untreated subjects to provide sufficient information on the treatment effect.
In cases where the treatment is assumed to have no net effect on the probability of survival, the naïve comparison of Y between the survivors in the treatment and control groups gives a consistent estimate of Δ + (1 -Ψ) × (δ -Δ). The error bounds of Table 1 apply to the naïve estimate in this situation. It follows that even in the absence of an effect on the survival probability, the naïve estimate may exhibit substantial bias if Pr(P 0 ) is not sufficiently large. Hence, the strategies of stratification and/or restriction may still be useful to control the asymptotic bias. Further, an a-priori assumption of a 0 treatment effect on the survival probability is usually difficult to justify. Instead, in our experience, practitioners usually justify application of the naïve approach based on a nonsignificant test of the treatment effect on mortality. However, in most cases, the precision of the effect estimate is not sufficient to rule out moderate effects on mortality, in which case assuming a 0 treatment effect on the survival probability when applying inferences to Y falsely inflates the precision of the analysis. Approaches such as those outlined in Sections 3 and 4 are necessary to properly incorporate the uncertainty in the treatment effect on mortality when performing inferences on Y.
We have focused on the setting in which the objective is to determine the average causal effect on Y as defined by a comparison EðY ð1Þ À Y ð0Þ jP 01 Þ between counterfactuals on P 01 . In some contexts, it may also be reasonable to view EðY ð1Þ jP 1 Þ À EðY ð0Þ jP 0 Þ itself as the desired estimand, as the contrast between E(Y (1) )
on P 1 and E(Y
) on P 0 represents a comparison of the marginal distributions of Y for the treatment and control groups on equivalent proportions of subjects who survive beyond the same percentile in the survival distributions on their assigned treatments [24] . In this case, ê(BSACE) is consistent for the target estimand E (Y Second, a limitation of the approach in this manuscript is that nonparametric estimates of h(J) may be unstable unless the follow-up time for survival substantially exceeds the follow-up time J for the longitudinal endpoint for a sufficient number of patients. Alternative estimates assuming parametric survival models may provide more stable estimation in some settings. Third, our simulation studies are limited in scope, and further work evaluating finite sample performance is needed, particularly when h * (J) is equal or close to J. Fourth, we have addressed the potential bias resulting from effect modifiers for the treatment effect on mortality by applying stratification to alter the subset of patients over which the causal effect of the treatment on Y is defined. Additional work needs to be done to investigate conditions under which stratification reduces bias. An alternative approach meriting consideration is to continue to define the balanced SACE on the subgroup P 01 , but apply conventional methods for covariate adjustment (e.g., inverse weighting) to control for confounding when comparing Y between P 1 and P 0 .
